ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL
-
Narrado por:
-
De:
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Haifaa Abdulhaq, University of California, San Francisco, US. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) treatment in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
In this interview, Abdulhaq discusses 3-year follow-up results from the phase III STARGLO trial (NCT04408638) of Glofit-GemOx vs rituximab (R)-GemOx in patients with R/R DLBCL who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT). They also discuss the efficacy and safety of Glofit-GemOx in clinically relevant patient subgroups.
This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.